Filing Flows › Organogenesis Holdings (ORGO) › Capital expenditures
Organogenesis Holdings (ORGO) capital expenditures by quarter
Organogenesis Holdings' capital expenditures were $3.1M in Q1 2026 (first quarter 2026), -32% from Q4 2025. Over the last 3 quarters it ranged from $2.2M (Q3 2025) to $4.7M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $3.1M | -32% | — |
| Q4 2025 | $4.7M | +108% | — |
| Q3 2025 | $2.2M | — | — |
Q1 2026 at a glance
Organogenesis Holdings, Q1 2026: revenue $37.2M (-57% year over year), operating margin -185.1%, net loss $53.2M, operating cash flow $21.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Organogenesis Holdings' capital expenditures?
Organogenesis Holdings' capital expenditures were $3.1M in Q1 2026 (first quarter 2026), -32% from Q4 2025.
How has Organogenesis Holdings' capital expenditures changed?
Over the last 3 quarters it ranged from $2.2M (Q3 2025) to $4.7M (Q4 2025).
Q1 2026 results → · How Organogenesis Holdings makes money →